


Tentative Program

10th International Conference on
**Cancer Research &
Drug Development**

 November 03-05, 2025 | Boston, MA



**Four Points by Sheraton Wakefield Boston
Hotel & Conference Center**
One Audubon Rd, Wakefield, MA



Exhibitor



AcroCyte Therapeutics is a cell-based precision medicine company. Their current focus lies in utilizing their core technology, R3CE—rapid, reproducible, rare cell expansion—to assist clinical treatment and scientific research. R3CE is a robust cell proliferation and expansion platform that can enable 3D cell culture from any specimen within 2 weeks, even when the cells are extremely rare. They are a driven team of scientists, industry leaders, and entrepreneurs deeply committed to integrating 3D cell culture and medicine to drive changes in precision medicine and, in turn, save lives.

<https://www.acrocyte.com/>

Welcome to the **10th International Conference on Cancer Research and Development (Cancer R&D 2025)**, a prestigious three-day congress devoted to advancing the field of basic, preclinical, and translational cancer research. Hosted by United Scientific Group, a distinguished non-profit organization committed to the progression of cancer research, Cancer R&D serves as a platform to foster innovation, cultivate knowledge, and encourage meaningful connections and collaborations within the global cancer research community.

Conference Highlights:

Cutting-edge Research: Cancer R&D 2025 will showcase the latest breakthroughs in cancer research across a diverse range of topics, spanning from fundamental studies to translational applications.

Inspiration for Innovation: The conference aims to inspire and catalyse innovation within the cancer research community, encouraging participants to push boundaries and explore new avenues in the fight against cancer.

Building Knowledge: Attendees will gain insights into the most recent discoveries, methodologies, and advancements in the field, contributing to the collective knowledge base of cancer research.

Date:

November 03-05, 2025

Venue:

Four Points by Sheraton Wakefield Boston Hotel & Conference Center
One Audubon Rd
Wakefield, MA, 01880
United States



Scientific Sessions

- Cancer Progression and Prognosis
- Cancer Metastasis
- Cancer Resistance
- Cancer Microenvironment
- The Microbiome and Cancer
- Novel Approaches to Detect Cancer Early
- Cancer Genetics and Biomarkers
- Precision Oncology
- Computational Biology and AI in Cancer
- Therapeutic Development
- Cancer Vaccines
- Cancer Immunotherapies: Monotherapy and Combinations
- Cellular Therapies for Cancer
- Cancer Radiation Therapy
- Targeted Therapy
- Novel Drug Development in Cancer
- Advances in Organ Specific Cancer Research
- Breast Cancer
- Brain Tumors
- Gastrointestinal Malignancies
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Sarcoma Biology
- Neuroendocrine Cancer

CRD-2025 CONFERENCE SCHEDULE

November 03, 2025

DAY-01

TIME	TALK/SESSION
07:30-08:00	Registrations and Badge Pickup
08:00-11:00	Plenary Session
11:00-11:15	Networking Break
11:15-13:00	Keynote Session-1
13:00-13:35	Group Photo & Networking Lunch
13:35-16:15	Keynote Session-2
16:15-16:30	Networking Break
16:30-17:40	Poster Session

November 04, 2025

DAY-02

TIME	TALK/SESSION
08:00-10:00	Session-I
10:00-10:15	Networking Break
10:15-12:55	Session-I
12:55-13:25	Networking Lunch
13:25-16:10	Session-II
16:10-16:20	Networking Break
16:20-17:40	Session-II

November 05, 2025

DAY-03

TIME	TALK/SESSION
08:00-10:00	Session-III
10:00-10:15	Networking Break
10:15-12:55	Session-III
12:55-13:25	Networking Lunch
13:25-16:10	Session-IV
16:05-16:20	Networking Break
16:20-17:00	Session-V
17:00	Departures


Join Zoom Meeting

To be updated

Meeting ID: To be updated

Passcode: To be updated

Plenary - Keynote Speakers



Douglas R. Green, St. Jude Children's Research Hospital, TN
Flatliners: Near Death Experiences in Cancer Cells



Raghu Kalluri, The University of Texas MD Anderson Cancer Center, TX
Title to be Updated



A Thomas Look, Dana-Farber Cancer Institute, Harvard Medical School, MA
Title to be Updated



Eytan Rupp, NCI, National Institutes of Health, MD
Towards Fast and Accessible Precision Oncology



Ethan Dmitrovsky, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.
National Institutes of Health, MD
CDK2 Inhibitors Eradicate Aneuploid Cancers: Promise Meets Resistance



Michael B Yaffe, Massachusetts Institute of Technology, MA
Title to be Updated



Keith T. Wilson, Vanderbilt University Medical Center, TN
Eukaryotic Translation Initiation Factor 5A and Hypusination in Colorectal Cancer



Ying-Chih Chang, CEO, Acrocyte Therapeutics Inc., Taiwan
Title to be Updated



Geeta Upadhyay, Uniformed Services University of the Health Sciences, MD
Novel Immuno-Oncology Targets for Solid Cancer



Georg F Weber, University of Cincinnati, OH
Title to be Updated

Poster Presentations

Aliyah Dalier, University of Massachusetts Amherst

Genome-Wide DNA Methylation as a Biomarker for Individual Breast Cancer Risk

Ashley Banas, University of Massachusetts Amherst

Does Chronic Inflammation Alter DNA Methylation in Breast Epithelial Cells?

Harshini Bapanapalli, University of Texas at Dallas

Engineered Virus like Particles for Targeted Tumor Immunotherapy

Ryan Stewart, The University of Tampa

Investigating Antioxidant Mechanisms on Drug Resistant Breast Cancer

Andrew Reidenbaugh, University of Tampa

Identifying Mechanisms of Antioxidant Combination Treatments on Drug Resistant Breast Cancer

Sultan Ahmed, University of Michigan

Investigating Functional and Structural Differences in EML4-ALK Variants using PASTE Gene Editing

Rajanti Dey, University of Michigan

Clinical Mutations that Confer Resistance to Asciminib

Linh Thi Tuong Nguyen, Taiwan International Graduate Program in Molecular Medicine, Academia Sinica

Targeting Lipid Rafts and Receptor Signaling with CY001: A Repurposed Antipsychotic Strategy for Drug-Resistant Non-Small Cell Lung Cancer

KIM HONGDUK, Seoul National University / Graduate School of International Agricultural Technology

Regulation of Tumor Growth and the Tumor Microenvironment by IFN- γ -Primed Stem Cell-Derived Exosomes

KIM TAEMIN, Seoul National University / Graduate School of International Agricultural Technology

Regulation of Tumor Growth and the Tumor Microenvironment by IFN- γ -Primed Stem Cell-Derived Exosomes

Tran Vo, DePauw University

Adverse Effects and Safety Considerations of Nanoparticle-Based Immune Checkpoint Inhibitor Therapy: A Systematic Review


Join Zoom Meeting

To be updated

Meeting ID: To be updated

Passcode: To be updated

CANCER BIOLOGY & CELLULAR THERAPIES IN CANCER




Yan Peng, University of Texas Southwestern Medical Center, TX
2025 Updates on Breast Cancer Biomarkers in Clinical Practice



Soona Shin, Cincinnati Children's Hospital Medical Center, OH
Role of Hepatic Progenitor Cells in Chronic Liver Disease and Cancer



Prasad Dandawate, University of Kansas Medical Center, KS
Title to be Updated



Shantel Angstadt, NCI, National Institutes of Health, MD
A Novel V β TCR-targeting Bifunctional Agent Combined with PD-1 Blockade in Checkpoint Refractory Cancer Models



Stefanie Galban, University of Michigan, MI
Title to be Updated



Maria Bustamante Molina, Massachusetts General Hospital Disparities Research Unit, MA
The Impact of Medicaid Expansion Under the Affordable Care Act on Breast Cancer Diagnosis, Treatment, and Mortality: A Systematic Review



Jun Wan, Indiana University School of Medicine, IN
DiCE Uncovers Critical Marker Genes in Prostate Cancer Through Network Modeling



Shreya Parthasarathi, Institute of Bioinformatics, Manipal Academy of Higher Education, India
A landscape of altered ion channels across tumor types

CANCER IMMUNOTHERAPY



Jing Hong Wang, University of Pittsburgh School of Medicine, PA
Determinants Underlying the Divergent Outcomes of Immune Checkpoint Inhibitors in Head and Neck Cancers



Jutatip Panaampon, Kumamoto University, Japan, Dana-Farber Cancer Institute, MA
An Unleashing the Power of Innate Immune Cells for Cancer Immunotherapy



Alice Cheung, Duke-NUS Medical School, Singapore General Hospital, Singapore
 $\gamma\delta$ T Cells in Nasopharyngeal Carcinoma: Implications for Adoptive Cell Therapy



Lucas Ferrari de Andrade, Icahn School of Medicine at Mount Sinai, NY
Harnessing Natural Killer cells for Cancer Immunotherapy



Elias Bou Farhat, Brigham and Women's Hospital, MA
Benchmarking Mismatch Repair Testing for Patients with Cancer Receiving Immunotherapy



Uyen Le, DePauw University, IN
Adverse Effects and Safety Considerations of Nanoparticle-Based ImmuneCheckpoint Inhibitor Therapy: A Systematic Review

Join Zoom Meeting

To be updated

Meeting ID: To be updated

Passcode: To be updated

CANCER TARGETED THERAPY



Ana M. Gamero, Lewis Katz School of Medicine at Temple University, PA
Targeting Molecular Pathways in Solid Tumors: Identifying Mechanisms and Opportunities




Kristen Fousek, NCI, National Institutes of Health, MD
Treatment of Neuroendocrine Tumors with NK-based Therapies




Shamim Mollah, Washington University in St. Louis School of Medicine, MO
Epigenetic Profiling of Curcumin on Histone Signatures in Breast Cancer using 3D Network



Zohar Sachs, University of Minnesota, MN
Title to be Updated



Rahul Aras, Iterion Therapeutics, Inc
Phase 1/2 trial of the Downstream Wnt/ β -catenin Inhibitor, Tegavivint, in Patients with Advanced Hepatocellular Carcinoma (aHCC)



Benjamin T. Spike, The University of Utah, UT
Title to be Updated

NOVEL DRUG DEVELOPMENT IN CANCER



Hannelore V Heemers, Lerner Research Institute Cleveland Clinic, OH
Title to be Updated



Dmitriy Minond, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, FL
Modulation of Spliceosomal Proteins hnRNP H1 and H2 Induces Immunogenicity of Melanoma Cells and In Vivo Immune Response



Michael Goldstein, Johns Hopkins University, MD
Title to be Updated



Jessica Kuehn-Hajder, University of Minnesota, MN
Title to be Updated



Xi Chen, MD Anderson Cancer Center, TX
Title to be Updated

CANCER RESISTANCE & TUMOR MICROENVIRONMENT



John D Schuetz, St. Jude Children's Research Hospital, TN
Title to be Updated




Anthony Faber, VCU Massey Comprehensive Cancer Center, VA
Pharmaceutical cBAF Restoration to Treat Synovial Sarcoma

VIRTUAL TALKS




Pooja Jain, Drexel University College of Medicine, PA
How One Leukemia Virus Reactivates Another Silent Cancer-Causing Virus - Tale of Two Viruses and Extracellular Vesicles



Wei Li, Penn State College of Medicine, PA
Title to be Updated



Romi Gupta, The University of Alabama at Birmingham, AL
Title to be Updated




Chuanxi Cai, University of Virginia, VA
MG53 Suppresses the Tumor Growth via Transcriptional Inhibiting the Expression of KIF11 in Pancreatic Cancer




Yaqing Zhang, University of Michigan Medical School, MI
Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage in Pancreatic Cancer



Frederick H Silver, Rutgers, the State University of New Jersey, NJ
Rapid Identification of Cancerous Lesions Using Vibrational Optical Coherence Tomography



Devkarn Sandhu, TIGMER, TX
Malignant Behavior: A Case of Solitary Fibrous Tumor



Govardhan Patirla, AIIMS Guwahati
Title to be Updated



Xiumei (Mae) Huan, Indiana University School of Medicine, IN
Title to be Updated

We wish to see you at

CRD-2025

November 03-05, 2025 | Boston, MA

Organized by



UNITED Scientific
Group
A non-profit organization

USG United Scientific Group

(A non-profit organization)

8105, Rasor Blvd - Suite #112, PLANO, TX 75024

Tel: +1-469-854-2280/81; **Fax:** +1-469-854-2278; **Email:** crd@uniscigroup.org

Web: <https://cancer.unitedscientificgroup.org/>